Research Analysts’ Recent Ratings Changes for Rapport Therapeutics (RAPP)

A number of research firms have changed their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 5/9/2026 – Rapport Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
• 4/22/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
• 4/21/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Rapport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $66.00 price target on the stock.
• 4/9/2026 – Rapport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.
• 3/25/2026 – Rapport Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/14/2026 – Rapport Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $39.99, for a total value of $808,797.75. Following the sale, the insider owned 246,426 shares of the company’s stock, valued at $9,854,575.74. The trade was a 7.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $40.32, for a total value of $17,176,521.60. Following the completion of the transaction, the insider owned 6,709,228 shares of the company’s stock, valued at approximately $270,516,072.96. This represents a 5.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 764,398 shares of company stock valued at $30,413,657. 13.57% of the stock is currently owned by company insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.